Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

The tick salivary protein sialostatin L inhibits the Th9-derived production of the asthma-promoting cytokine IL-9 and is effective in the prevention of experimental asthma.

Horka, Helena; Staudt, Valérie; Klein, Matthias; Taube, Christian; Reuter, Sebastian; Dehzad, Nina; Andersen, John F; Kopecky, Jan; Schild, Hansjörg; Kotsyfakis, Michalis; Hoffmann, Markus; Gerlitzki, Bastian; Stassen, Michael; Bopp, Tobias; Schmitt, Edgar.
J Immunol; 188(6): 2669-76, 2012 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-22327077
Ticks developed a multitude of different immune evasion strategies to obtain a blood meal. Sialostatin L is an immunosuppressive cysteine protease inhibitor present in the saliva of the hard tick Ixodes scapularis. In this study, we demonstrate that sialostatin L strongly inhibits the production of IL-9 by Th9 cells. Because we could show recently that Th9-derived IL-9 is essentially involved in the induction of asthma symptoms, sialostatin L was used for the treatment of experimental asthma. Application of sialostatin L in a model of experimental asthma almost completely abrogated airway hyperresponsiveness and eosinophilia. Our data suggest that sialostatin L can prevent experimental asthma, most likely by inhibiting the IL-9 production of Th9 cells. Thus, alternative to IL-9 neutralization sialostatin L provides the basis for the development of innovative therapeutic strategies to treat asthma.
Selo DaSilva